Journal Article

New insights into pediatric idiopathic pulmonary hemosiderosis: the French RespiRare® cohort

Epaud, Ralph, Nathan, Nadia, Fayon, Mickael, Taytard, Jessica, Deschildre, Antoine, de Blic, Jacques, Michon, Delphine, Lubrano, Marc, Clement, Annick, Chiron, Raphaël, Cros, Pierrick, Troussier, Françoise, Corvol, Harriet, Reix, Philippe, Mahloul, Malika

2013

Overview

Background Idiopathic pulmonary hemosiderosis (IPH) is a rare cause of alveolar hemorrhage in children and its pathophysiology remains obscure. Classically, diagnosis is based on a triad including hemoptysis, diffuse parenchymal infiltrates on chest X-rays, and iron-deficiency anemia. We present the French pediatric cohort of IPH collected through the French Reference Center for Rare Lung Diseases (RespiRare®, http://www.respirare.fr ). Methods Since 2008, a national network/web-linked RespiRare® database has been set up in 12 French pediatric respiratory centres. It is structured as a medical recording tool with extended disease-specific datasets containing clinical information relevant to all forms of rare lung diseases including IPH. Results We identified 25 reported cases of IPH in children from the database (20 females and 5 males). Among them, 5 presented with Down syndrome. Upon diagnosis, median age was 4.3 [0.8-14.0] yrs, and the main manifestations were: dyspnea (n = 17, 68%), anemia (n = 16, 64%), cough (n = 12, 48%), febrile pneumonia (n = 11, 44%) and hemoptysis (n = 11, 44%). Half of the patients demonstrated diffuse parenchymal infiltrates on chest imaging, and diagnosis was ascertained either by broncho-alveolar lavage indicating the presence of hemosiderin-laden macrophages (19/25 cases), or lung biopsy (6/25). In screened patients, initial auto-immune screening revealed positive antineutrophilic cytoplasmic antibodies (ANCA) (n = 6, 40%), antinuclear antibodies (ANA) (n = 5, 45%) and specific coeliac disease antibodies (n = 4, 28%). All the patients were initially treated by corticosteroids. In 13 cases, immunosuppressants were introduced due to corticoresistance and/or major side effects. Median length of follow-up was 5.5 yrs, with a satisfactory respiratory outcome in 23/25 patients. One patient developed severe pulmonary fibrosis, and another with Down syndrome died as a result of severe pulmonary hemorrhage. Conclusion The present cohort provides substantial information on clinical expression and outcomes of pediatric IPH. Analysis of potential contributors supports a role of auto-immunity in disease development and highlights the importance of genetic factors.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V
• Subject: Adolescent / Antibodies / Child / Child, Preschool / Corticosteroids / Diagnosis / Dosage and administration / Down syndrome / Drug therapy / Female / Genetics / Hemosiderosis / Hemosiderosis - diagnosis / Hemosiderosis - drug therapy / Hemosiderosis, Pulmonary / Human Genetics / Humans / Immunosuppressive agents / Immunosuppressive Agents - therapeutic use / Infant / Iron deficiency anemia / Life Sciences / Lung diseases / Lung Diseases - diagnosis / Lung Diseases - drug therapy / Male / Medical research / Medicine / Medicine & Public Health / Patient outcomes / Pediatric respiratory diseases / Pharmacology/Toxicology / Rare diseases / Viral antibodies